Accès ouvert · CC BY

Clinical Evaluation of the PANDAA LASV RT-PCR Assay in Sierra Leone

Article scientifique 2026 Sciences de la santé Anglais

Résumé

Abstract Molecular diagnosis of Lassa fever is complicated by extensive Lassa virus genetic diversity and limited laboratory capacity in endemic settings. The RealStar® Lassa Virus RT-PCR Kit 2.0 is a commonly used commercial dual-target assay for LASV detection, but its two-target format requires separate amplification reactions, increasing reagent use and workflow complexity. We present the diagnostic evaluation of the single-reaction, adaptive PANDAA LASV RT-PCR assay with the dual-target RealStar® Lassa Virus RT-PCR Kit 2.0 using 94 archived serum samples from Sierra Leone. 79 of these samples had valid paired results, and we report a positive percent agreement of 78.12% (95% CI 61.25%–88.98%), negative percent agreement of 93.62% (95% CI 82.84%–97.81%), and an overall agreement of 87.34% (95% CI 78.24%–92.98%); Cohen κ was 0.73 (95% CI 0.58–0.89). PANDAA showed substantial agreement and offers a potentially efficient single-well format, but further optimisation and prospective evaluation are needed.

Citer ce document

Grant, D. S., Thompson, C. R., Sandi, J. D., Manjia, M., Kallon, T. M. P. S., Kamara, M., Fofanah, I. U., Edwards, T., Fletcher, T. E., & Byrne, R. L. (2026). Clinical Evaluation of the PANDAA LASV RT-PCR Assay in Sierra Leone. medRxiv. https://doi.org/10.64898/2026.10.30.26366846

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 16/11/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 4

Téléchargements (hors robots) : 0

Méthode de comptage